The GSDMD Knockout SK-HEP-1 Polyclonal Cells product comprises a heterogeneous population of SK-HEP-1 cells that have undergone CRISPR/Cas9-mediated disruption of the GSDMD gene. This polyclonal knockout pool is designed for researchers studying pyroptosis and inflammasome signaling, providing a loss-of-function model in a liver sinusoidal endothelial context. The polyclonal format ensures a diverse genetic background while eliminating functional GSDMD expression, enabling robust analysis of GSDMD-dependent cellular processes.
The SK-HEP-1 host cell line is derived from a human hepatic adenocarcinoma and exhibits key endothelial features, including angiogenic capacity and maintenance of a blood-tissue barrier phenotype. It is extensively employed as a surrogate for liver sinusoidal endothelial cells, facilitating studies on hepatic sinusoidal biology, tumor-endothelial interactions, and metastatic colonization. This model combines epithelial origin with endothelial functionality, making it a valuable tool for investigating liver-specific cellular processes and disease mechanisms.
GSDMD functions as the pivotal pore-forming effector of pyroptosis, a lytic inflammatory cell death. It is activated following proteolytic cleavage by inflammatory caspases??caspase-1, -4, -5, and -11??which are themselves regulated by canonical and non-canonical inflammasomes, including NLRP3, AIM2, NLRC4, and Pyrin, assembled through the adaptor ASC. The released N-terminal fragment of GSDMD translocates to the plasma membrane, where it binds cardiolipin and phosphatidylinositol phosphates, oligomerizes, and inserts to form large pores. These pores disrupt cellular integrity, causing pyroptotic cell death and enabling the release of mature interleukin-1?? (IL-1??), interleukin-18 (IL-18), and damage-associated molecular patterns such as HMGB1. This signaling axis positions GSDMD as a central mediator of inflammatory responses.
In the SK-HEP-1 liver sinusoidal endothelial model, GSDMD disruption enables dissection of pyroptotic signaling specifically within the hepatic microenvironment. This is particularly relevant for conditions where endothelial cell death and inflammation contribute to pathogenesis, such as sepsis-associated liver injury, inflammatory bowel disease, and hepatic metastasis. The knockout cells allow researchers to interrogate how loss of GSDMD-mediated pore formation and cytokine secretion alters endothelial barrier function, immune cell recruitment, and tumor cell adhesion, providing insights into disease mechanisms that are otherwise masked in non-endothelial systems.
Key applications include monitoring caspase-1 activation and GSDMD cleavage via Western blotting, quantifying pyroptotic cell death through lactate dehydrogenase (LDH) release assays, and measuring IL-1?? and IL-18 secretion by ELISA. Live-cell imaging can visualize pore formation dynamics, while flow cytometry permits assessment of cell death kinetics. The cells also support RT-qPCR analysis of inflammasome component transcripts and immunofluorescence localization of GSDMD. Combined with pharmacological inhibitors, this model facilitates drug screening for pyroptosis modulators and investigation of non-canonical inflammasome pathways. For further technical details and ordering information, please contact Ascent Research.
